目次

Table of Content

1. Introduction To DLL3 Targeted Therapies
1.1 Overview
1.2 History and Evolution Of DLL3 Targeted Therapies
1.3 Role Of DLL3 As Diagnostic and Prognostic Markers

2. DLL3 Targeting Approaches, Mechanism and Commercial Aspects
2.1 Antibody Drug Conjugates
2.2 Antibodies
2.3 Cell Therapies
2.4 Antibody Radionuclide Conjugates
2.5 Antibody Photoabsorber/Photosensitizer Conjugate

3. DLL3 Targeted Therapies Proprietary Platforms
3.1 Platforms Used To Develop DLL3 Targeted Therapies
3.2 Potential Platforms For DLL3 Targeted Therapies Development

4. Imdelltra - 1st Approved DLL3 Targeted Drug
4.1 Clinical Overview and Patent Insight
4.2 Treatment Cycle Pricing and Dosage Analysis
4.3 Sales Analysis

5. DLL3 Targeted Therapies Market and Clinical Trends Insights
5.1 Current Market Trends, Developments and Clinical Trials Assessment
5.2 Future Commercialization Opportunity

6. DLL3 Targeted Therapies Research and Market Trends by Region
6.1 US
6.2 UK
6.3 EU
6.4 Canada
6.5 Australia
6.6 China

7. Global DLL3 Targeted Therapies Clinical Development and Market Insight By Indication
7.1 Small Cell Lung Cancer
7.2 Large Cell Neuroendocrine Cancer
7.3 Neuroendocrine Prostate Cancer
7.4 Gastroenteropancreatic Neuroendocrine Tumors
7.5 Glioma

8. Global DLL3 Targeted Drugs Clinical Trials Overview
8.1 By Company
8.2 By Fast Track Status
8.3 By Indication
8.4 By Location
8.5 By Patient Segment
8.6 By Phase

9. Global DLL3 Targeted Drugs Clinical Trials By Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II

10. Marketed DLL3 Targeted Drugs Clinical Trials By Company, Indication and Phase

11. DLL3 Targeted Therapies Market Dynamics
11.1 Favorable Market and Clinical Development Parameters
11.2 Challenges and Restraints

12. Key Companies Involved In Research and Development Of DLL3 Targeted Therapies
12.1 Abdera Therapeutics
12.2 Allogene Therapeutics
12.3 Amgen
12.4 Boehringer Ingelheim
12.5 Chugai Pharmaceutical
12.6 Gensun Biopharma
12.7 Harpoon Therapeutics
12.8 ImaginAb Inc
12.9 Legend Biotech
12.10 Molecular Partners
12.11 Phanes Therapeutics
12.12 Qilu Pharmaceutical
12.13 Shanghai Affinity Biopharmaceutical
12.14 ZAI Lab

List of Figures
Figure 2-1: Antibody Drug Conjugates - Mechanism Of Action
Figure 2-2: BiTE - Amgen
Figure 2-3: HPN328 - Structure
Figure 2-4: Rova-IR700 - Mechanism
Figure 3-1: T-Charge Platform - Features
Figure 3-2: BiTEandreg; Antibody Construct
Figure 3-3: TMALIN - ADC Advantages
Figure 3-4: TMALIN - ADC Structure
Figure 3-5: TriTAC - T-Cell Engagers Structure
Figure 3-6: TriTAC - Advantages
Figure 3-7: PACbodyandtrade; Platform
Figure 3-8: ATACCbodyandtrade; Platform
Figure 3-9: SPECpairandtrade; Platform
Figure 3-10: ROVEr Platform - Process
Figure 3-11: RPT - Advantages
Figure 3-12: Dual-Ig Technology - Antibody Structure and Mechanism
Figure 3-13: AlloCAR T - Process
Figure 3-14: AlloCAR T - Features
Figure 3-15: Alluminoxandtrade; Platform - Drug Structure
Figure 3-16: Rakuten Medical - Photoimmunotherapy Process
Figure 4-1: Imdelltra - Approval Year By Region
Figure 4-2: US - Price of Supply of Imdelltra Intravenous Powder (US$), January’2025
Figure 4-3: EU - Price Of Imdelltra Intravenous Powder (US$), January’2025:
Figure 4-4: Global - Imdelltra Sales (US$ Million), 2024
Figure 4-5: Imdelltra - Global Sales By Quarter (US$ Million), Q2 and Q3’2024
Figure 4-6: Imdelltra - US Sales (US$ Million), 2024
Figure 4-7: Imdelltra- US Sales By Quarter (US$ Million), Q2 and Q3’2024
Figure 5-1: Global - DLL3 Targeted Therapy Market (US$ Million), 2024
Figure 5-2: Global - DLL3 Targeted Therapy Market Sales (US$ Million), Q2 and Q3’2024
Figure 7-1: DLL3 - Small Cell Lung Cancer
Figure 7-2: DeLLphi-301 Phase 2 Study - Initiation and Completion Year
Figure 7-3: DeLLphi-304 Phase 2 Study - Initiation and Completion Year
Figure 7-4: DAREONandtrade;-5 Phase 2 Study - Initiation and Completion Year
Figure 7-5: PT217X1101 Phase 1 Study - Initiation and Completion Year
Figure 7-6: HPN328 Phase 1 Study - Initiation and Completion Year
Figure 7-7: LB2102-1001 Phase 1 Study - Initiation and Completion Year
Figure 7-8: NCT05507593 Phase 1 Study - Initiation and Completion Year
Figure 7-9: DLL3 - Large Cell Neuroendocrine Cancer
Figure 8-1: Global - DLL3 Targeted Drugs Clinical Trials By Company (Number), 2025
Figure 8-2: Global - DLL3 Targeted Drugs Clinical Trials By Fast Track Status (Number), 2025
Figure 8-3: Global - DLL3 Targeted Drugs Clinical Trials By Indication (Number), 2025
Figure 8-4: Global - DLL3 Targeted Drugs Clinical Trials By Location (Number), 2025
Figure 8-5: Global - DLL3 Targeted Drugs Clinical Trials By Patient Segment (Number), 2025
Figure 8-6: Global - DLL3 Targeted Drugs Clinical Trials By Phase (Number), 2025
Figure 11-1: DLL3 Targeted Therapies - Market Drivers and Opportunities
Figure 11-2: DLL3 Targeted Therapies - Market Challenges and Restraints

List of Tables
Table 6-1: US - FDA Designated DLL3 Targeted Therapies, 2025
Table 7-1: Large Cell Neuroendocrine Cancer - Candidates In Clinical Trials, 2025
Table 7-2: Neuroendocrine Prostate Cancer - Candidates In Clinical Trials, 2025
Table 7 3: Gastroenteropancreatic Neuroendocrine Tumors - Candidates In Clinical Trials, 2025
Table 7-4: Glioma - Candidates In Clinical Trials, 2025